|
| Status |
Public on Sep 11, 2013 |
| Title |
NB4, Ago3-associated mRNAs, biological rep1 |
| Sample type |
RNA |
| |
|
| Source name |
NB4 cell line, 4'-thiouridine and UV treated
|
| Organism |
Homo sapiens |
| Characteristics |
tissue: human acute promyelocytic leukemia
genotype: cells carry the t(15;17) PML-RARA fusion gene
age: cells were harvested after 48 - 72 h
rna subtype: Ago3-associated mRNAs
|
| Extracted molecule |
total RNA |
| Extraction protocol |
The 4 Ago antibodies were obtained from our cooperation partner Prof. Dr. Gunter Meister from University Regensburg and were manufactured in house. TRIzol extraction of Ago- / isotype control-associated and total RNA was performed according to the manufacturer's instructions.
|
| Label |
biotin
|
| Label protocol |
Biotinylated aRNA was prepared according to the standard Affymetrix protocol from (GeneChip 3' IVT Express Kit Manual, 2008-2009, Affymetrix).
|
| |
|
| Hybridization protocol |
Following fragmentation, aRNA was hybridized on Affymetrix Human Genome U133 2.0 Arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 450 (performed by the core facility BMFZ Düsseldorf).
|
| Scan protocol |
GeneChips were scanned using the GCS 3000 from Affymetrix (performed by the core facility BMFZ, Düsseldorf).
|
| Description |
Identification of Ago3-associated mRNAs
|
| Data processing |
The data were analyzed with RMAExpress v.1.0.4 for Windows, using quantile normalization and the median polish signal estimation algorithm.
|
| |
|
| Submission date |
Jan 24, 2012 |
| Last update date |
Sep 11, 2013 |
| Contact name |
Pablo Landgraf |
| E-mail(s) |
pablo.landgraf@gmx.de
|
| Organization name |
Heinrich-Heine University Düsseldorf
|
| Department |
Clinic of Pediatric Oncology, Hematology and Clinical Immunology
|
| Street address |
Moorenstraße 5
|
| City |
Düsseldorf |
| ZIP/Postal code |
40225 |
| Country |
Germany |
| |
|
| Platform ID |
GPL571 |
| Series (1) |
| GSE35320 |
microRNAs distinguish cytogenetic subgroups in pediatric AML and contribute to complex regulatory networks in AML-relevant pathways |
|
